Palmitoylethanolamide (PEA), a naturally occurring lipid amide between palmitic acid and ethanolamine is suggested to be a compound able to fulfill the criteria of a multi-factorial therapeutic approach in Alzhemer’s disease. This is suggested by a number of pharmacologists in a recent article: Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer’s disease.
They focus on the anti-inflammatory and neuroprotective activities of systemic administration of PEA in adult male rats given intrahippocampal injection of beta amyloid 1-42 (Aβ 1-42).
Aβ 1-42 infusion gives rise to severe changes of biochemical markers related to reactive gliosis, amyloidogenesis, and tau protein hyperphosphorylation.
PEA was able to restore the Aβ 1-42-induced alterations through PPAR-α involvement.
Furthermore, PEA reduced memory deficits in this ALheimer model.
The authors concluded:
These data disclose novel findings about the therapeutic potential of PEA, and suggest novel strategies that hopefully could have the potential not just to alleviate the symptoms but also to modify disease progression.
Source: Scuderi C, Stecca C, Valenza M, Ratano P, Bronzuoli MR, Bartoli S, Steardo L, Pompili E, Fumagalli L, Campolongo P, Steardo L. Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer’s disease. Cell Death Dis. 2014 Sep 11;5:e1419. doi: 10.1038/cddis.2014.376.